MassChallenge Startups Create Impact

2,458

Startups Accelerated

$6.2B

Funding Raised

$3B

Revenue Generated

157,000+

Jobs Created

Our startups

Be inspired. Search our startups.

Clear  
DEBN
DEBN

Prostate cancer is the most common malignancy diagnosed among men.Transrectal biopsy is a gold standard for detecting it. Patients undergoing this procedure are exposed to urinary tract infections leading even to sepsis. Treatment cost of prostate biopsy-related complications and insurance payouts is estimated at $1.7 bn in the USA and EU. DEBN delivers the optimal antibiotic combination directly to the prostate, precisely at the place where potential infections start reducing risk significantly
DEBN is a medical company developing a novel prostate biopsy needle for urologists which will reduce infectious complication rate.

Connect with DEBN

2019

2019 Finalist Switzerland

Sub industry

Medical Devices

Mission

MassChallenge strengthens the global innovation ecosystem by accelerating high-potential startups across all industries, from anywhere in the world.